1 completed, 1 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
Follow AT9283: new trials by email Literature Review of AT9283 trials Research Report on AT9283
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma AT9283 - Multiple Myeloma | Phase 2 | Completed | NCIC Clinical Trials Group | 8 | 2011-02-15 | 2023-08-04 |
| Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias AT9283 - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | Astex Pharmaceuticals, Inc. | 48 | 2006-09-01 | 2024-08-02 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Primary Myelofibrosis (1) · Recurrence (1)
Astex Pharmaceuticals, Inc. (1) · NCIC Clinical Trials Group (1)
Canada (1) · United States (1)
Tony Reiman (1)